03-17 Paratek Pharmaceuticals, Inc. acquired Radius Health, Inc. from B-Flexion Advisors (UK) LLP, Gurnet Point Capital Limited, OrbiMed Advisors LLC, Patient Square Capital, LP and Webster Equity Partners, L.P. CI
01-12 B-Flexion Advisors (UK) LLP agreed to acquire remaining 57% stake in Radius Health, Inc. from affiliates of Patient Square Capital, LP, Webster Equity Partners V, L.P., fund managed by Webster Equity Partners, L.P. CI
23-09-19 EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Radius Health, Inc for Binosto for the United States CI
23-07-27 Radius Health, Inc. Announces the Appointment of Al Medwar as Senior Vice President and Corporate Development CI
23-04-06 Radius Health, Inc. Appoints Erika Tooman as Senior Vice President/ General Counsel CI
23-03-20 Theramex Enters into an Exclusive Licensing Agreement with Radius Health Inc, to Commercialise ELADYNOS in the European Economic Area, United Kingdom, Australia and Brazil CI
22-12-30 Radius Health, Inc. announced that it has received funding from Webster Equity Partners, LLC CI
22-12-20 Radius Health's Tymlos® (Abaloparatide) Receives U.S. FDA Approval as A Treatment to Increase Bone Density in Men with Osteoporosis At High Risk for Fracture CI
22-08-16 Ambrx Biopharma Names Kate Hermans Interim CEO MT
22-08-15 Radius Health, Inc. Announces Board Changes CI
22-08-15 Radius Health, Inc. Enters into Credit Agreement CI
22-08-15 Radius Health, Inc.(NasdaqGM:RDUS) dropped from NASDAQ Composite Index CI
22-08-15 Radius Health, Inc.(NasdaqGM:RDUS) dropped from S&P TMI Index CI
Manager TitleAgeSince
Chief Executive Officer - 2022-10-11
Chief Tech/Sci/R&D Officer - 2020-12-14
Corporate Officer/Principal - 2024-06-24
Director TitleAgeSince
Director/Board Member - 2022-07-31
Director/Board Member - 2022-08-14
Director/Board Member - 2022-08-14
Date Insider Type Main position Quantity % Market Cap. Importance
8/15/22 Tender

Director

33,195 0.0697%
8/15/22 Tender

Director

15,500 0.0326%
8/15/22 Issuer sale

CEO and President; Director

75,000 0.1576%
Change 5-day change 1-year change 3-year change Capi.($)
-0.20%-1.37% - - 480M
-4.10%-8.54%+40.05%+66.99% 63.29B
-0.41%+3.27%+10.46%+72.82% 54.89B
+0.74%+4.04%+12.18%+88.71% 53.28B
+0.61%+2.69%+27.75%+50.97% 45.81B
-1.08%+2.19%+21.92%+131.38% 43.46B
-3.39%-0.83%+254.27%+571.04% 40.23B
-1.67%+6.70%+14.42%+56.67% 33.45B
+2.61%-3.69%+30.76%+0.59% 23.7B
+1.30%+4.94%+38.23%+28.59% 23.76B
Average -0.56%+1.06%+50.00%+118.64% 42.43B
Weighted average by Cap. -0.95%+0.89%+48.00%+121.95%
Logo Radius Health, Inc.
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).
Employees
293
  1. Stock Market
  2. Stocks
  3. RDUS Stock